INCB123667 + palbociclib + fulvestrant

This combination consists of **INCB123667**, a selective cyclin-dependent kinase 2 (CDK2) inhibitor, combined with **palbociclib**, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and **fulvestrant**, a selective estrogen receptor degrader (SERD). INCB123667 targets aberrant cell cycle progression by inhibiting CDK2, which is crucial for cancer cells with cyclin E1 overexpression or CCNE1 amplification, often found in gynecologic and other solid tumors[1][3]. Palbociclib blocks CDK4/6 to prevent cell cycle progression from G1 to S phase. Fulvestrant is an antiestrogen that degrades the estrogen receptor, blocking hormone signaling in tumors reliant on estrogen signaling. This triple combination is under clinical investigation for treating advanced/metastatic solid tumors, especially breast cancer and other tumors showing resistance to CDK4/6 inhibitors or with CCNE1 amplification[3]. INCB123667 is being developed by Incyte. Palbociclib is marketed by Pfizer, and fulvestrant is marketed by AstraZeneca.

Brand names

Ibrance (palbociclib)Faslodex (fulvestrant)